查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836927

呼吸系统疾病检测市场按检测类型、成分、年龄层、技术、检测目的、疾病类型和最终用户划分－2025-2032 年全球预测

Respiratory Disease Testing Market by Test Type, Component, Age Group, Technology, Test Purpose, Diseases Type, End Users - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，呼吸系统疾病检测市场将成长至 104.3 亿美元，复合年增长率为 6.10%。

主要市场统计数据
基准年2024年 64.9亿美元
预计2025年 68.6亿美元
预测年份：2032年 104.3亿美元
复合年增长率（%） 6.10%

现代呼吸检测生态系统的框架以及组织必须应对的策略挑战，以协调诊断、交付模式和患者需求

呼吸系统检测领域正经历快速发展，这得归功于日益融合的临床需求、技术进步以及医疗服务模式的转变。本报告概述了重新定义住院、门诊和居家环境中检测设计、交付和使用方式的驱动因素。报告重点关注血液检测、影像学检查和肺功能评估等诊断模式，并强调了仪器、耗材和软体解决方案之间相互作用，从而支持现代化的工作流程。

临床医生和实验室管理人员日益寻求能够加快获得可操作结果、与电子健康记录整合并支援远端监控途径的诊断解决方案。同时，支付方和医疗系统也优先考虑能够提高病患管理效率并实现早期疗育。这些压力与分子诊断和先进影像技术的成熟同步出现，它们共同扩大了医疗保健提供者可获得的具有临床意义的诊断结果的范围。

本章将阐明利害关係人必须回答的核心问题，为后续的深入分析奠定基础：如何使采购和研发重点与相关人员群体的需求保持一致，如何管理试剂和设备供应链的复杂性，以及如何大规模运作先进的检测技术。本书将帮助读者理解后续章节，探讨结构性变化、关税影响、细分市场细微差别、区域动态、竞争行动以及可行的策略步骤。

一项重大的产业转型，透过分散化、软体整合和策略伙伴关係关係重新定义测试范式，重塑临床工作流程

呼吸系统疾病检测领域正因临床、供应架构和技术能力的变革而再形成。变革的关键载体之一是床边诊断和家用诊断的加速发展，这使得检测从集中式实验室转移到需要便携性、易用性和连接性的分散式医疗机构。随着支援长时间重复、低侵入性测量的设备和检测的兴起，这种分散化趋势推动了对纵向监测的关注。

同时，演算法影像分析和云端读取平台正在增强影像工作流程，缩短读取时间，并催生外包读取和影像即服务等新服务。分子诊断已拓展其临床应用范围和技术稳健性，实现了多重检测和高灵敏度检测，从而实现更早的干预。虽然试剂和套件的创新仍然是差异化优势，但从仪器控製到结果解读和报告的软体整合正成为决定性的竞争优势。

供应链的韧性和监管的完整性也正在改变製造商和供应商的产品设计和上市方式。仪器製造商、试剂供应商和软体供应商之间正在建立战略伙伴关係，透过提供整合解决方案而非单一组件来简化采购流程并支援端到端临床工作流程。总而言之，这些转变需要製定灵活的商业策略，并将临床需求与产品蓝图紧密结合。

全面评估近期关税政策如何影响整个诊断价值链的筹资策略、采购行为和供应链弹性

美国加征关税的累积效应正在为呼吸侦测供应链的各个环节带来压力，影响采购决策、采购週期和成本结构。诊断设备和耗材进口关税的变化促使製造商和经销商重新评估其生产布局和供应商多元化策略，这通常会加速考虑近岸外包和跨区域采购，以减少在单一国家/地区的业务风险。这种动态需要在接近性、人事费用、合规成本以及快速试剂补充所需的物流敏捷性之间进行权衡。

为应对这项挑战，一些供应商优先考虑在岸组装，确保区域製造基地以降低运输相关延误和关税波动带来的风险，并协商长期供应协议以对冲价格波动。医疗保健机构和实验室正在透过延长采购前置作业时间和尽可能整合供应商来应对这项挑战。透明的整体拥有成本分析至关重要，相关人员现在必须将与关税相关的情境纳入采购评估和临床规划中。

监管和报销方面的考虑进一步加剧了关税的影响。当投入成本上升导致单次检测支出增加时，监管机构和付款方可能会更严格地审查临床效用，而医疗服务提供者可能会优先考虑那些能够明显改善护理路径的检测。因此，公司必须透过清晰的价值陈述、营运效益以及改善的疗效和效率抵消成本增加的证据来证明价格调整的合理性。

详细的细分观点揭示了诊断产品设计、临床效用和商业化如何与测试模式、技术和最终用户保持一致

透过按检测类型、组件、年龄层、技术、检测目标、疾病类型和最终用户对市场进行分析，细分市场层面的分析揭示了整个检测生态系统中差异化的商业机会和营运需求。根据检测类型，重点关注包含生化和免疫学测量的血液检测、用于结构评估的影像检查（包括胸部X光和电脑断层扫描）以及用于量化呼吸动态的肺功能测试。仪器、试剂/套件和软体的性能和市场策略因组件而异，例如，仪器需要资本规划，试剂需要低温运输物流和批次管理，而软体需要互通性和生命週期更新。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 扩大基于 CRISPR 的照护现场方法，快速检测呼吸道病原体
  • 引入人工智慧驱动的演算法来预测临床环境中的呼吸道感染疾病风险
  • 引进远端医疗整合家庭检体套件，增强远距呼吸诊断能力
  • 医院实验室越来越多地使用多重 PCR 检测新出现的空气传播病原体变体
  • 越来越多地使用穿戴式呼吸分析设备来即时、持续地监测呼吸生物标记
  • 推出云端连接检测平台，用于即时监测呼吸道感染疾病疫情
  • 新兴市场中，纸基横向流动化验在低成本呼吸道病毒筛检的应用日益普及
  • 用于全面分析呼吸道微生物组和发现病原体的新兴次世代定序工作流程

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 呼吸系统疾病检测市场（依检测类型）

  • 血液检查
  • 影像检查
    • 胸部X光检查
    • 电脑断层扫描
  • 肺功能检查

9. 呼吸系统疾病检测市场（按组件）

  • 装置
  • 试剂和套件
  • 软体

第 10 章呼吸系统疾病检测市场（依年龄层）

  • 成人
  • 老年人
  • 孩子们

第 11 章呼吸系统疾病检测市场（按技术）

  • 成像技术
  • 免疫检测
  • 微生物学
  • 分子诊断

第12章呼吸系统疾病检测市场（依检测目的）

  • 诊断
  • 监控
  • 预后
  • 筛检

第十三章呼吸系统疾病检测市场（依疾病类型）

  • 气喘
  • 慢性阻塞性肺病（COPD）
    • 慢性支气管炎
    • 气肿
  • 传染性呼吸道疾病
    • 流感
    • 肺炎
    • 结核
  • 肺癌

第 14 章呼吸系统疾病检测市场（按最终用户）

  • 诊断实验室
  • 居家照护环境
  • 医院和诊所
  • 研究办公室

第 15 章呼吸系统疾病检测市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第16章呼吸系统疾病检测市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章呼吸系统疾病检测市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • AstraZeneca PLC
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Biomerieux PLC
    • Charles River Laboratories
    • COSMED srl
    • Eurofins Viracor, LLC
    • F. Hoffmann-La Roche Ltd.
    • Fujifilm Holdings
    • GE Healthcare
    • Koninklijke Philips NV
    • Medtronic PLC
    • MGC Diagnostics Corporation by Caire Inc.
    • QIAGEN Group
    • ResMed
    • SDI Diagnostics, Inc.
    • Seegene Inc.
    • Seimens Healthineers AG
    • Thermo Fisher Scientific
Product Code: MRR-035AB9C0DAAD

The Respiratory Disease Testing Market is projected to grow by USD 10.43 billion at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.49 billion
Estimated Year [2025] USD 6.86 billion
Forecast Year [2032] USD 10.43 billion
CAGR (%) 6.10%

Framing the modern respiratory testing ecosystem and the strategic questions organizations must address to align diagnostics, delivery models, and patient needs

The respiratory disease testing environment is undergoing a period of rapid evolution driven by converging clinical needs, technological advances, and shifting care delivery models. This introduction distills the driving forces that are redefining how testing is designed, delivered, and consumed across inpatient, outpatient, and home-based settings. It frames the report's focus on diagnostic modalities that span blood assays, imaging, and pulmonary function evaluation while highlighting the interplay between instruments, consumables, and software solutions that enable modern workflows.

Clinicians and laboratory managers are increasingly demanding diagnostic solutions that reduce time to actionable result, integrate with electronic health records, and support remote monitoring pathways. At the same time, payers and health systems are prioritizing tests that improve patient management efficiency and enable earlier intervention. These pressures are occurring alongside technological maturation in molecular diagnostics and advanced imaging analytics, which together expand the range of clinically meaningful outputs available to providers.

This section sets the context for the deeper analysis that follows by articulating the core questions stakeholders must answer: how to align procurement and R&D priorities with patient population needs, how to manage supply chain complexity for reagents and instruments, and how to operationalize advanced testing technologies at scale. It prepares readers to interpret subsequent chapters that examine structural shifts, tariff impacts, segmentation nuances, regional dynamics, competitive behavior, and actionable strategy steps.

Critical industry transformations redefining testing paradigms through decentralization, software integration, and strategic partnerships that reshape clinical workflows

The landscape for respiratory disease testing is being reshaped by transformative shifts that cut across clinical practice, supply architecture, and technological capability. One primary vector of change is the acceleration of point of care and home-based diagnostics, which relocates testing out of centralized labs and into decentralized care settings that demand portability, ease of use, and connectivity. This decentralization is accompanied by stronger emphasis on longitudinal monitoring, which elevates devices and assays that can support repeated, low-burden measurements over time.

Concurrently, imaging workflows are being augmented by algorithmic image analysis and cloud-enabled reading platforms that compress interpretation timelines while creating novel services such as outsourced reads and imaging-as-a-service. Molecular diagnostics have expanded in clinical breadth and technical robustness, enabling multiplexed panels and high-sensitivity detection that informs earlier interventions. Reagent and kit innovation continues to be a differentiator, but the integration of software, from instrument control to result interpretation and reporting, is becoming a decisive competitive axis.

Supply chain resilience and regulatory alignment are also shifting how manufacturers and providers approach product design and market entry. Strategic partnerships between device makers, reagent suppliers, and software vendors are emerging to deliver integrated solutions rather than discrete components, thereby simplifying procurement and supporting end-to-end clinical workflows. Taken together, these shifts demand adaptive commercial strategies and closer alignment between clinical needs and product roadmaps.

Comprehensive assessment of how recent tariff policies have redirected sourcing strategies, procurement behavior, and supply chain resilience across the diagnostic value chain

The cumulative effect of tariff actions initiated in the United States has exerted pressure across multiple dimensions of the respiratory testing supply chain, influencing sourcing decisions, procurement cycles, and cost structures. Changes to import duties on diagnostic instruments and consumables have incentivized manufacturers and distributors to reassess manufacturing footprints and supplier diversification strategies, often accelerating exploration of nearshoring and multi-region sourcing to mitigate single-country exposure. This dynamic creates tradeoffs between proximity, labor and compliance costs, and the logistical agility needed for rapid reagent replenishment.

In response, some vendors are prioritizing onshore assembly or regional production hubs that reduce transit-related delays and exposure to tariff volatility, while others are negotiating long-term supply agreements that hedge pricing risk. Health systems and laboratories are reacting by lengthening lead times on procurement and by intensifying vendor consolidation efforts where feasible, seeking the predictability of bundled contracts even as they weigh the impact of higher landed costs. The need for transparent total cost of ownership analysis has become paramount; stakeholders must now incorporate tariff-related scenarios into procurement evaluations and clinical planning.

Regulatory and reimbursement considerations further compound the effects of tariffs. When elevated input costs translate into higher per-test expenditures, regulatory bodies and payers may scrutinize clinical utility more closely, and providers may prioritize tests that demonstrably improve care pathways. Consequently, companies will need to justify price adjustments with clear value narratives, operational benefits, and evidence that offsets cost increases through improved outcomes or efficiencies.

In-depth segmentation perspective revealing how diagnostic product design, clinical utility, and commercialization must align across test modalities, technologies, and end users

Segment-level analysis reveals differentiated opportunities and operational imperatives across the testing ecosystem when the market is parsed by test type, component, age group, technology, test purpose, disease type, and end user. Based on test type, attention is divided between blood tests that enable biochemical and immunologic readouts, imaging tests that include chest X-ray and computed tomography for structural evaluation, and pulmonary function tests that quantify respiratory mechanics, each of which addresses distinct clinical decision points and operational requirements. Based on component, performance and go-to-market strategies vary substantially for instruments, reagents and kits, and software, with instruments requiring capital planning, reagents demanding cold-chain logistics and lot management, and software hinging on interoperability and lifecycle updates.

Based on age group, clinical utility and product design must account for adults, geriatrics, and pediatrics, as each cohort presents unique sampling, compliance, and interpretative considerations. Based on technology, opportunities cluster around imaging technologies that deliver structural insights, immunoassays that offer targeted biomarker detection, microbiology platforms that support culture and organism identification, and molecular diagnostics that enable high-sensitivity nucleic acid detection. Based on test purpose, solutions differ markedly when oriented toward diagnosis, monitoring, prognosis, or screening, and product positioning must reflect the operational cadence and regulatory expectations inherent to each use case.

Based on disease type, product and service requirements align to clinical workflows for asthma, chronic obstructive pulmonary disease with its chronic bronchitis and emphysema subtypes, infectious respiratory diseases spanning influenza, pneumonia and tuberculosis, and lung cancer where staging and molecular profiling are central. Based on end users, diagnostic laboratories, home care settings, hospitals and clinics, and research laboratories each have distinct purchasing models, integration needs, and staffing capabilities that affect adoption pathways and support models. This segmentation framework clarifies where vendors should prioritize product enhancements, clinical validation efforts, and tailored go-to-market messaging.

Regional dynamics and market entry considerations that determine adoption, regulatory navigation, and supply chain configuration across major global healthcare regions

Regional dynamics significantly influence regulatory pathways, reimbursement environments, supply chain decisions, and adoption rates for respiratory disease testing innovations. In the Americas, healthcare delivery models and payer structures create a strong emphasis on demonstrating clinical utility and operational efficiency, driving demand for integrated diagnostic solutions that reduce downstream costs and support value-based care agreements. In Europe, Middle East and Africa, heterogeneity in regulatory frameworks and procurement practices necessitates flexible market entry strategies, localized clinical evidence generation, and partnerships with regional distributors to navigate reimbursement variability and capacity constraints.

In Asia-Pacific, rapid adoption of digital health infrastructure and significant investment in local manufacturing capacity create fertile conditions for scale-driven approaches, with governments and private health networks actively supporting diagnostic modernization initiatives. Cross-regional considerations include the need to tailor product configurations to local laboratory capabilities, to provide multilingual software interfaces, and to ensure that logistics models accommodate diverse cold-chain and customs environments. Additionally, companies must anticipate regional differences in disease prevalence, screening priorities, and clinical practice patterns when developing clinical validation strategies and commercial rollouts.

Taken together, geographic realities inform not only market access tactics but also R&D prioritization and manufacturing placement. Successful players adopt a regionally nuanced playbook that balances global platform efficiencies with locally adapted commercialization and service models to accelerate adoption and sustain operations across heterogeneous markets.

Strategic competitive behaviors and partnership models that drive differentiation through integrated platforms, evidence generation, and service excellence

Competitive behavior among companies in the respiratory diagnostics space is characterized by a mix of product specialization, platform expansion, and strategic collaborations that aim to deliver more complete clinical workflows. Instrument manufacturers continue to invest in modular platforms that support both core testing capabilities and future assay expansion, while reagent and kit suppliers focus on robustness, supply consistency, and simplified handling to lower the operational burden on laboratories and point of care settings. Software providers are increasingly differentiating through advanced analytics, connectivity to electronic health records, and features that support remote monitoring and telehealth integration.

Partnerships between device makers and software firms are producing bundled offerings that reduce integration friction and present a clearer value proposition to hospitals and diagnostic networks. Concurrently, joint development agreements with clinical research organizations and academic institutions are being used to build evidence for new assay claims and to accelerate regulatory submissions. Service and aftermarket offerings, such as managed reagent programs and remote instrument diagnostics, have become important revenue streams and customer retention levers. Companies that can demonstrate end-to-end reliability, rapid support response, and a clear pathway for clinical adoption are more likely to secure long-term contracts with health systems.

To compete effectively, firms must balance investments in core technological excellence with pragmatic commercial execution, investing in field service capabilities, training programs for clinical staff, and outcome-oriented evidence generation that resonates with procurement and clinical decision makers.

Concrete strategic initiatives that industry executives can implement to strengthen adoption, resilience, and commercial value across diagnostic portfolios

Industry leaders seeking to accelerate growth and build defensible positions in respiratory testing should pursue a set of pragmatic, actionable steps that align product development, go-to-market strategy, and operational resilience. First, prioritize interoperability and data integration capabilities so that instruments and software can plug into existing hospital systems and reporting workflows; this reduces adoption friction and supports clinical decision making. Second, strengthen supply chain diversification by qualifying secondary suppliers, exploring regional production partnerships, and implementing inventory strategies that buffer against tariff and logistics shocks.

Third, invest in clinical evidence that ties test results to measurable care improvements and operational savings; health systems and payers respond to clear demonstrations of value through changed clinical pathways. Fourth, design product lines with modularity in mind so that customers can scale offerings by purchasing incremental capabilities rather than replacing capital equipment. Fifth, expand service offerings to include managed reagents, remote maintenance, and training that reduce the operational burden on end users and create recurring revenue streams. Finally, adopt flexible commercial models-such as outcome-linked pricing, subscription access to software, and bundled solutions-that match the capital and operational constraints of different end users.

These actions should be executed in a coordinated manner across R&D, regulatory, commercial, and supply chain functions to ensure consistent messaging and efficient delivery of value to providers and patients.

Transparent mixed methods research design combining stakeholder interviews, technical validation, and scenario analysis to underpin the respiratory diagnostics findings

The research approach underpinning this analysis blended structured primary research with rigorous secondary synthesis and iterative triangulation to ensure accuracy and relevance. Primary inputs included in-depth interviews with clinical leaders, laboratory directors, procurement professionals, and industry executives to capture firsthand perspectives on adoption barriers, workflow constraints, and purchasing criteria. These qualitative insights were complemented by technical discussions with product development and supply chain specialists to understand manufacturing realities, reagent handling requirements, and software integration challenges.

Secondary research encompassed review of regulatory guidance, clinical literature, and public policy documents to contextualize technology adoption and reimbursement frameworks. Data synthesis applied cross-validation techniques that compared manufacturer claims, clinical protocol expectations, and end-user operational constraints to build a coherent narrative about where innovation is translating into practice. The methodology also incorporated scenario analysis to illuminate how policy shifts, such as tariff changes and regulatory updates, might alter strategic choices for manufacturers and providers.

Limitations are acknowledged where proprietary contractual terms and confidential supplier arrangements restrict visibility; where possible, the analysis highlights risk factors and suggests information gaps for future primary inquiry. Overall, the methodology emphasizes transparency, stakeholder diversity, and methodological rigor to support defensible conclusions and actionable recommendations.

Synthesis of diagnostic ecosystem drivers and strategic priorities that leaders must address to capitalize on innovation while managing operational and policy risks

In conclusion, the respiratory disease testing landscape is transitioning toward integrated solutions that blend robust instrumentation, reliable reagents, and intelligent software to meet evolving clinical and operational needs. Decentralization of testing and the rise of longitudinal monitoring change the calculus for product design, favoring portability, connectivity, and ease of use. Tariff dynamics and supply chain considerations add another layer of strategic complexity, compelling organizations to rethink manufacturing placement, supplier relationships, and procurement practices to preserve cost-effectiveness and continuity of supply.

Segmentation analysis highlights that different test types, technologies, disease targets, and end users require distinct value propositions and commercialization approaches. Regional differences further necessitate tailored market access plans and localized evidence generation. Competitive differentiation increasingly rests on the ability to deliver end-to-end value through service models, clinical validation, and interoperable platforms. For stakeholders across the ecosystem, success will be determined by the agility to adapt product strategies to clinical workflows, the foresight to manage supply chain exposure, and the commitment to generate evidence that resonates with clinicians and payers alike.

The insights presented here are intended to inform strategic planning, guide tactical investments, and support cross-functional alignment as organizations navigate the complex and rapidly changing respiratory diagnostics environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of CRISPR-based point-of-care assays for rapid detection of respiratory pathogens
  • 5.2. Deployment of AI-driven algorithms for predictive respiratory infection risk assessment in clinical settings
  • 5.3. Adoption of telehealth-integrated home sampling kits enhancing remote respiratory diagnostics capabilities
  • 5.4. Growth of multiplex PCR panels targeting emerging airborne pathogen variants in hospital laboratories
  • 5.5. Rising use of wearable breath analysis devices for continuous monitoring of respiratory biomarkers in real time
  • 5.6. Implementation of cloud-connected testing platforms enabling real-time surveillance of respiratory outbreaks
  • 5.7. Increased development of paper-based lateral flow assays for low-cost respiratory virus screening in emerging markets
  • 5.8. Emergence of next-generation sequencing workflows for comprehensive respiratory microbiome profiling and pathogen discovery

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Respiratory Disease Testing Market, by Test Type

  • 8.1. Blood Tests
  • 8.2. Imaging Tests
    • 8.2.1. Chest X-Ray
    • 8.2.2. Computed Tomography
  • 8.3. Pulmonary Function Tests

9. Respiratory Disease Testing Market, by Component

  • 9.1. Instruments
  • 9.2. Reagents & Kits
  • 9.3. Software

10. Respiratory Disease Testing Market, by Age Group

  • 10.1. Adults
  • 10.2. Geriatrics
  • 10.3. Pediatrics

11. Respiratory Disease Testing Market, by Technology

  • 11.1. Imaging Technologies
  • 11.2. Immunoassays
  • 11.3. Microbiology
  • 11.4. Molecular Diagnostics

12. Respiratory Disease Testing Market, by Test Purpose

  • 12.1. Diagnosis
  • 12.2. Monitoring
  • 12.3. Prognosis
  • 12.4. Screening

13. Respiratory Disease Testing Market, by Diseases Type

  • 13.1. Asthma
  • 13.2. Chronic Obstructive Pulmonary Disease (COPD)
    • 13.2.1. Chronic Bronchitis
    • 13.2.2. Emphysema
  • 13.3. Infectious Respiratory Diseases
    • 13.3.1. Influenza
    • 13.3.2. Pneumonia
    • 13.3.3. Tuberculosis
  • 13.4. Lung Cancer

14. Respiratory Disease Testing Market, by End Users

  • 14.1. Diagnostic Laboratories
  • 14.2. Home Care Settings
  • 14.3. Hospitals & Clinics
  • 14.4. Research Laboratories

15. Respiratory Disease Testing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Respiratory Disease Testing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Respiratory Disease Testing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Abbott Laboratories
    • 18.3.2. AstraZeneca PLC
    • 18.3.3. Becton, Dickinson and Company
    • 18.3.4. Bio-Rad Laboratories, Inc.
    • 18.3.5. Biomerieux PLC
    • 18.3.6. Charles River Laboratories
    • 18.3.7. COSMED srl
    • 18.3.8. Eurofins Viracor, LLC
    • 18.3.9. F. Hoffmann-La Roche Ltd.
    • 18.3.10. Fujifilm Holdings
    • 18.3.11. GE Healthcare
    • 18.3.12. Koninklijke Philips N.V
    • 18.3.13. Medtronic PLC
    • 18.3.14. MGC Diagnostics Corporation by Caire Inc.
    • 18.3.15. QIAGEN Group
    • 18.3.16. ResMed
    • 18.3.17. SDI Diagnostics, Inc.
    • 18.3.18. Seegene Inc.
    • 18.3.19. Seimens Healthineers AG
    • 18.3.20. Thermo Fisher Scientific

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. RESPIRATORY DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. RESPIRATORY DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RESPIRATORY DISEASE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHEST X-RAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MICROBIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY ASTHMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC BRONCHITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY EMPHYSEMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY PNEUMONIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL RESPIRATORY DISEASE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST PURPOSE, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY DISEASES TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY INFECTIOUS RESPIRATORY DISEASES, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY END USERS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)

TABLE 29